Last updated: March 1, 2026
What is KEVZARA?
KEVZARA (sarilumab) is a monoclonal antibody developed by Sanofi and Regeneron Pharmaceuticals. It targets interleukin-6 receptor (IL-6R) and is approved primarily for rheumatoid arthritis. Its formulation involves a subcutaneous injection, requiring specific excipients for stability, solubility, and delivery.
What are the Key Excipients in KEVZARA?
KEVZARA's formulation typically includes:
- Histidine: Acts as a buffer to maintain pH stability.
- Sodium chloride: Maintains isotonicity.
- L-histidine hydrochloride monohydrate: Stabilizes the antibody.
- Polysorbate 80: Serves as a surfactant to prevent aggregation.
- Sucrose: Protects the antibody during freeze-thaw cycles.
- Water for injection: Solvent.
These excipients ensure the drug's stability, reduce aggregation, and enable a shelf life of approximately two years under refrigerated conditions.
How Does Excipient Strategy Impact KEVZARA’s Development?
Stability and Shelf Life
Excipients like sucrose and polysorbate 80 enhance protein stability. Stability data shows KEVZARA maintains efficacy under refrigerated storage for two years, aligned with typical monoclonal antibody standards.
Administration and Patient Compliance
Formulation aims for subcutaneous injection, minimizing injection volume. The excipient mix reduces viscosity and potential injection site reactions.
Manufacturing and Cost Optimization
Using biosimilar or alternative excipients can reduce production costs. For instance, replacing polysorbate 80 (linked with nodal reactions) with alternative surfactants could optimize safety and costs in future formulations.
Commercial Opportunities from Excipient Optimization
Biosimilar Development
Biosimilars targeting KEVZARA are increasingly developing. Optimizing excasant composition can reduce immunogenicity risks and improve stability, providing differentiation in the competitive biosimilar market.
New Indication Expansion
KEVZARA is under investigation for COVID-19, cytokine release syndrome, and other autoimmune conditions. Customizing excipients can adapt the formulation for these indications, especially for intravenous or auto-injector delivery methods.
Cost Reduction and Market Penetration
Switching to generic excipients or novel stabilizers can reduce manufacturing costs by 10-20%. Lower-cost formulations can broaden access in emerging markets, expanding sales volume.
Innovative Delivery Platforms
Developing sustained-release or auto-injector formulations involves novel excipients that allow controlled release or reduced injection frequency, creating premium product lines with higher price points.
Regulatory and Patent Strategies
Patent protection extends to specific excipient combinations. Novel excipient formulations can generate new patent protections, delaying biosimilar entry.
Key Challenges in Excipient Optimization
- Regulatory hurdles require extensive stability and safety data.
- Potential immunogenicity linked to certain surfactants (e.g., polysorbate 80).
- Compatibility issues with new excipients and existing manufacturing processes.
- Ensuring scalability and supply chain robustness for alternative excipients.
Competitive Landscape
| Drug |
Manufacturer |
Excipients |
Formulation Type |
Market Focus (Indication) |
| KEVZARA |
Sanofi/Regeneron |
Histidine, sucrose, polysorbate 80 |
Liquid injectable |
Rheumatoid arthritis, psoriatic arthritis |
| Actemra (tocilizumab) |
Roche |
Arginine, polysorbate 80, sucrose |
Injectable |
Rheumatoid arthritis |
| Olumiant (baricitinib) |
Eli Lilly |
Not applicable (oral) |
Oral tablet |
Rheumatoid arthritis |
Market and Regulatory Considerations
- The global rheumatoid arthritis market reached USD 21.4 billion in 2021.
- KEVZARA holds approximately 6% market share among IL-6 receptor antagonists.
- Excipients are scrutinized by agencies like the FDA and EMA, especially concerning immunogenicity and stability.
- Biosimilar pathways favor formulations with simplified excipients but require demonstrating comparability.
Regulatory Pathways for Excipient Changes
Changes to excipients post-approval require supplemental filings:
- FDA: 351(k) biosimilar pathway or 505(b)(2) supplement for formulation modifications.
- EMA: Variation procedures requiring comparability studies.
Approval depends on demonstrating unchanged safety, efficacy, and stability.
Conclusion
Optimizing excipient strategies for KEVZARA offers avenues to improve stability, reduce costs, and expand indications. Innovations in excipient combinations and delivery platforms can facilitate market share growth and regulatory advantages.
Key Takeaways
- KEVZARA’s current formulation relies on stabilizing excipients common among monoclonal antibodies.
- Formulation advancements can lower manufacturing costs and improve patient compliance.
- Excipient modifications can enable new indications and delivery methods.
- Biosimilar development can benefit from stable, cost-effective excipient profiles.
- Regulatory pathways for excipient changes emphasize the need for comprehensive stability and safety data.
FAQs
Q1: What are the most critical excipients in KEVZARA’s formulation?
Histidine buffer, sucrose, polysorbate 80, sodium chloride, and water for injection are essential for stability, isotonicity, and solubilization.
Q2: How can excipient optimization impact KEVZARA’s marketability?
It can reduce production costs, enable new delivery formats, and facilitate expansion into additional indications.
Q3: Are there safety concerns with current excipients like polysorbate 80?
Polysorbate 80 has been linked to rare hypersensitivity reactions; alternatives may improve safety profiles.
Q4: Can excipient changes delay biosimilar competition?
Yes, unique or optimized excipient formulations can provide patent or regulatory barriers.
Q5: What regulatory hurdles exist for excipient modifications?
Increases in stability or safety must be validated through stability, immunogenicity, and efficacy data submitted in supplemental filings.
References
[1] U.S. Food and Drug Administration. (2021). Guidance for industry: Changes to an approved NDA or BLA.
[2] European Medicines Agency. (2020). Guideline on similar biological medicinal products.
[3] Regal, S. (2022). Advances in monoclonal antibody formulations. Pharmaceutical Technology.
